Global InformationExenatide information
 Single conformer of the solution NMR structure of exenatide. PDB: 7MLL | |
| Clinical data | |
|---|---|
| Pronunciation | /ɛɡzˈɛnətaɪd/ ⓘ |
| Trade names | Byetta, Bydureon, Bydureon BCise, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605034 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Metabolism | proteolysis |
| Elimination half-life | 2.4 h |
| Excretion | Kidney |
| Identifiers | |
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | 100.212.123 |
| Chemical and physical data | |
| Formula | C184H282N50O60S |
| Molar mass | 4186.63 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
  (what is this?) (verify) | |
Exenatide, sold under the brand name Byetta among others, is a medication used to treat type 2 diabetes.[7] It is used together with diet, exercise, and potentially other antidiabetic medication.[7] It is a treatment option after metformin and sulfonylureas.[8] It is given by injection under the skin.[7]
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection.[7] Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury.[7] Use in pregnancy and breastfeeding is of unclear safety.[9] Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics.[7] It works by increasing insulin release from the pancreas and decreases excessive glucagon release.[7]
Exenatide was approved for medical use in the United States in 2005.[7] In 2019, it was the 312th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ Cite error: The named reference
UKByettalabelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
UKBydureonlabelwas invoked but never defined (see the help page). - ^ "Bydureon- exenatide injection, suspension, extended release Bydureon- exenatide kit". DailyMed. 28 February 2020. Retrieved 2 December 2020.
- ^ "Bydureon BCise- exenatide injection, suspension, extended release". DailyMed. 28 February 2020. Retrieved 2 December 2020.
- ^ "Byetta- exenatide injection". DailyMed. 28 February 2020. Retrieved 2 December 2020.
- ^ a b c d e f g h "Exenatide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 684–685. ISBN 978-0-85711-338-2.
- ^ "Exenatide Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ "Exenatide - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.